Bottlenecks in the Acute Stroke Care System during the COVID-19 Pandemic in Catalonia.


Journal

Cerebrovascular diseases (Basel, Switzerland)
ISSN: 1421-9786
Titre abrégé: Cerebrovasc Dis
Pays: Switzerland
ID NLM: 9100851

Informations de publication

Date de publication:
2021
Historique:
received: 26 01 2021
accepted: 02 04 2021
pubmed: 24 5 2021
medline: 24 9 2021
entrez: 23 5 2021
Statut: ppublish

Résumé

The COVID-19 pandemic resulted in significant healthcare reorganizations, potentially striking standard medical care. We investigated the impact of the COVID-19 pandemic on acute stroke care quality and clinical outcomes to detect healthcare system's bottlenecks from a territorial point of view. Crossed-data analysis between a prospective nation-based mandatory registry of acute stroke, Emergency Medical System (EMS) records, and daily incidence of COVID-19 in Catalonia (Spain). We included all stroke code activations during the pandemic (March 15-May 2, 2020) and an immediate prepandemic period (January 26-March 14, 2020). Primary outcomes were stroke code activations and reperfusion therapies in both periods. Secondary outcomes included clinical characteristics, workflow metrics, differences across types of stroke centers, correlation analysis between weekly EMS alerts, COVID-19 cases, and workflow metrics, and impact on mortality and clinical outcome at 90 days. Stroke code activations decreased by 22% and reperfusion therapies dropped by 29% during the pandemic period, with no differences in age, stroke severity, or large vessel occlusion. Calls to EMS were handled 42 min later, and time from onset to hospital arrival increased by 53 min, with significant correlations between weekly COVID-19 cases and more EMS calls (rho = 0.81), less stroke code activations (rho = -0.37), and longer prehospital delays (rho = 0.25). Telestroke centers were afflicted with higher reductions in stroke code activations, reperfusion treatments, referrals to endovascular centers, and increased delays to thrombolytics. The independent odds of death increased (OR 1.6 [1.05-2.4], p 0.03) and good functional outcome decreased (mRS ≤2 at 90 days: OR 0.6 [0.4-0.9], p 0.015) during the pandemic period. During the COVID-19 pandemic, Catalonia's stroke system's weakest points were the delay to EMS alert and a decline of stroke code activations, reperfusion treatments, and interhospital transfers, mostly at local centers. Patients suffering an acute stroke during the pandemic period had higher odds of poor functional outcome and death. The complete stroke care system's analysis is crucial to allocate resources appropriately.

Identifiants

pubmed: 34023822
pii: 000516309
doi: 10.1159/000516309
pmc: PMC8247826
doi:

Substances chimiques

Fibrinolytic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

551-559

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Anna Ramos-Pachón (A)

Stroke Unit, Hospital Germans Trias i Pujol, Badalona, Spain, aramos@igtp.cat.

Álvaro García-Tornel (Á)

Stroke Unit, Hospital Universitari Vall D'Hebron-VHIR, Barcelona, Spain.

Mònica Millán (M)

Stroke Unit, Hospital Germans Trias i Pujol, Badalona, Spain.

Marc Ribó (M)

Hospital Universitari Vall D'Hebron-VHIR, Barcelona, Spain.

Sergi Amaro (S)

Stroke Unit, Hospital Clínic, Barcelona, Spain.

Pere Cardona (P)

Stroke Unit, Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain.

Joan Martí-Fàbregas (J)

Stroke Unit, Department of Neurology, Santa Creu i Sant Pau Hospital, Barcelona, Spain.

Jaume Roquer (J)

Stroke Unit, Department of Neurology, Mar Hospital, Barcelona, Spain.

Yolanda Silva (Y)

Stroke Unit, Hospital Universitari Josep Trueta, Girona, Spain.

Xavier Ustrell (X)

Department of Neurology, Hospital Universitari Joan XXIII, Tarragona, Spain.

Francisco Purroy (F)

Department of Neurology, Stroke Unit, Hospital Arnau de Vilanova, Lleida, Spain.

Manuel Gómez-Choco (M)

Department of Neurology, Hospital Moisés Broggi, Sant Joan Despí, Spain.

José Zaragoza-Brunet (J)

Department of Neurology, Hospital Verge de la Cinta, Tortosa, Spain.

David Cánovas (D)

Department of Neurology, Hospital Parc Taulí, Sabadell, Spain.

Jurek Krupinski (J)

Department of Neurology, Hospital Mútua Terrassa, Terrassa, Spain.

Natalia Mas Sala (NM)

Department of Neurology, Hospital Sant Joan de Déu - Fundació Althaia, Manresa, Spain.

Ernest Palomeras (E)

Department of Neurology, Hospital Mataró, Mataró, Spain.

Dolores Cocho (D)

Department of Neurology, Hospital General Granollers, Granollers, Spain.

Laura Redondo (L)

Emergency Department, Hospital Universitari Vic, Vic, Spain.

Carmen Repullo (C)

Emergency Department, Fundació Hospital Seu Urgell, La Seu d'Urgell, Spain.

Eduardo Sanjurjo (E)

Emergency Department, Hospital del Pallars, Tremp, Spain.

Dolors Carrión (D)

Emergency Department, Hospital Mora Ebre, Mora Ebre, Spain.

Mercè López (M)

Emergency Department, Hospital Figueres, Figueres, Spain.

M Cruz Almendros (MC)

Emergency Department, Hospital Palamós, Palamós, Spain.

Miquel Barceló (M)

Emergency Department, Hospital Cerdanya, Puigcerdà, Spain.

Jordi Monedero (J)

Medical Director, Hospital Igualada, Igualada, Spain.

Esther Catena (E)

Department of Neurology, Consorci Sanitari Alt Penedès-Garraf, Vilafranca del Penedés, Spain.

Maria Rybyeba (M)

Emergency Department, Fundació Hospital d'Olot, Olot, Spain.

Gloria Diaz (G)

Emergency Department, Hospital Campdevànol, Campdevànol, Spain.

Xavier Jiménez-Fàbrega (X)

Sistema d'Emergències Mèdiques, Barcelona, Spain.

Silvia Solà (S)

Sistema d'Emergències Mèdiques, Barcelona, Spain.

Verónica Hidalgo (V)

Hospital del Mar, Barcelona, Spain.

Maria Jesus Pueyo (MJ)

Departament de Salut de Catalunya, Catsalut, Barcelona, Spain.

Natàlia Pérez de la Ossa (N)

Catalan Stroke Program, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Xabier Urra (X)

Stroke Unit, Hospital Clínic, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH